BPC-157 dosage calculator: how the math actually works

Last updated 2026-07-23

What does a BPC-157 dosage calculator actually calculate?

A BPC-157 dosage calculator is a unit-conversion tool. It takes three inputs (how many milligrams of peptide are in the vial, how much bacteriostatic water you added, and what dose in micrograms someone wants to inject) and spits out a volume, usually in units on an insulin syringe or in milliliters. That's it. It does not know whether the dose itself is safe, effective, or even remotely close to anything studied in humans. This distinction matters more than most vendor pages let on. The math behind reconstitution is simple algebra: concentration equals total peptide mass divided by total liquid volume, and injection volume equals desired dose divided by concentration. A calculator that gets this wrong will hurt you through under- or over-dosing relative to whatever target number you or your provider picked. But the calculator has no opinion, and shouldn't have one, on what that target number should be. That decision belongs to a prescriber, not a slider on a website. We built this explainer because most 'dosage calculator' pages people find are either bare unit converters with a big buy now button underneath, or they quietly present rat study doses as if they were human protocols. Neither is honest. The rest of this article walks through the actual math, then walks through what the human and animal evidence does and doesn't support, so you can use a calculator as a math tool without mistaking it for a clinical one.

How do I calculate BPC-157 reconstitution and injection volume?

Reconstitution math has two steps: figuring out concentration, then figuring out injection volume for a target dose. Here's the arithmetic a BPC-157 reconstitution calculator runs behind the scenes. Step 1: Concentration = total peptide (mcg) / total bacteriostatic water added (mL). A 5 mg vial (5,000 mcg) reconstituted with 2 mL of water gives a concentration of 2,500 mcg/mL, or 250 mcg per 0.1 mL (10 units on an insulin syringe, which is marked in units where 100 units = 1 mL). Step 2: Injection volume = target dose (mcg) / concentration (mcg/mL). If your concentration is 2,500 mcg/mL and the target is 250 mcg, you'd draw 0.1 mL, or 10 units on a standard U-100 insulin syringe. Here's a reference table showing how the same 5 mg vial plays out at different reconstitution volumes. This is pure math, nothing here is a dosing recommendation. | Water added | Concentration | Volume for 250 mcg | Volume for 500 mcg |

Is there an FDA-approved or standard BPC-157 human dose?

No. There is no FDA-approved dose for BPC-157 because BPC-157 is not an approved drug for any condition. You can check this yourself in Drugs@FDA, the FDA's own database of approved drug products ^[1]. BPC-157 does not appear there because it has never completed the agency's approval pathway for any indication. BPC-157 also is not on either FDA bulks list that governs what compounding pharmacies are permitted to use. The 503A Bulks List under 21 CFR 216.23 covers substances pharmacies compounding for individual patients may use ^[2], and the 503B Bulks List under 21 CFR 216.24 covers larger outsourcing facilities ^[3]. FDA's own bulk drug substances page for 503A compounding explains the standard these nominations are judged against ^[4], and the current nominated substances list is where products under review sit while FDA evaluates them ^[5]. BPC-157's regulatory status has shifted over time as FDA has reviewed nominations, so anyone sourcing it should check the current list rather than assume yesterday's status still holds. Because there's no approved product, there's no package insert, no FDA-reviewed dosing table, and no clinical trial phase that established a maximum tolerated dose in humans the way you'd see for an approved drug. Any number you see quoted as 'standard' is coming from either a compounding pharmacy's internal protocol, a small pilot study, or extrapolation from animal research. None of those carry FDA sign-off. That's not necessarily disqualifying, but it's a different category of evidence than an approved drug label, and calculators that present a default dose as though it were settled science are overstating what's known.

Where do the numbers in BPC-157 dosage calculators come from?

Almost entirely from two places: rodent studies and a handful of small human pilot studies. Neither source should be read as a validated human dosing protocol, and the difference between the two is worth being explicit about. The bulk of the BPC-157 literature is preclinical. A 2025 literature and patent review in Pharmaceuticals catalogued the peptide's proposed mechanisms and reported applications across multiple organ systems, but the underlying data it reviews is overwhelmingly from animal models ^[6]. A 2019 review in Cell and Tissue Research on musculoskeletal soft tissue healing describes BPC-157's effects on tendon, ligament, and muscle repair specifically in rodent models ^[7], and a 2018 paper in Current Pharmaceutical Design on angiogenic growth factors similarly draws its healing-related conclusions from animal tissue studies, including gastrointestinal, tendon, ligament, muscle, and bone healing work ^[8]. A widely cited 2011 study in the Journal of Applied Physiology found BPC-157 promoted tendon outgrowth, cell survival, and cell migration in an explant and rat model of tendon healing ^[9]. Doses used in these studies are typically reported in micrograms or nanograms per kilogram of animal body weight, injected or applied locally, in controlled lab conditions. Scaling a rat dose to a human dose is not a simple weight ratio; species differences in metabolism, absorption, and receptor biology make that kind of naive conversion unreliable, which is exactly why no dosing calculator should present an animal-study number as a human starting point. Human data does exist, but it's thin. A 2021 pilot study in Alternative Therapies in Health and Medicine looked at intra-articular BPC-157 injection for multiple types of knee pain ^[10], and a 2024 pilot study in the same journal examined BPC-157's effect on symptoms in patients with interstitial cystitis ^[11]. Both are small, early-stage human studies, not large randomized controlled trials, and neither establishes a dose-response curve the way phase 2 or phase 3 trials would for an approved drug. A 2025 systematic review in the HSS Journal specifically examined BPC-157's emerging use in orthopaedic sports medicine and is worth reading if you want the most current summary of where the clinical (as opposed to purely preclinical) evidence stands ^[12].

How does a BPC-157/TB-500 blend dosage calculator differ from a BPC-157-only one?

A BPC-157 + TB-500 blend dosage calculator has to solve two concentration problems at once, because most blended vials contain two different peptides at two different total masses in the same liquid volume. The math is the same per-peptide concentration equation run twice, then you need to make sure the injection volume you land on for one peptide's target dose doesn't accidentally underdose or overdose the other. Say a blended vial has 10 mg BPC-157 and 10 mg TB-500 reconstituted in 2 mL. Concentration for each peptide is 5,000 mcg/mL. If your target BPC-157 dose is 250 mcg, that's 0.05 mL, and because both peptides are in the same solution at the same ratio, that same 0.05 mL delivers roughly 250 mcg of TB-500 too, since the masses were equal going into the vial. If the vial ratio isn't 1:1 (some blends use 10 mg BPC-157 to 5 mg TB-500, for instance), the two concentrations differ and you cannot independently target both doses at once. You're locked into whatever ratio the vial was mixed at. This is the single biggest source of dosing confusion with blend calculators. People assume they can dial in 'my BPC-157 dose' and 'my TB-500 dose' separately from one blended vial, and they can't, not unless the mixing ratio happens to match what they want for both. If independent dosing of each peptide matters to you, two separate single-peptide vials give you actual control; a pre-mixed blend does not. On the evidence side, it's worth being clear that essentially none of the human or animal literature cited in this article studied a BPC-157/TB-500 combination specifically. The studies referenced here, including the tendon healing work ^[9], the vascular research ^[13], and the pilot human trials [10, 11], all looked at BPC-157 in isolation. Claims about a combined effect are extrapolation, not direct evidence. For a side-by-side look at how the two peptides differ mechanistically and in the literature that exists for each, see BPC-157 vs TB-500.

What dose ranges show up in the BPC-157 research and vendor literature?

Because there's no approved human dose, what circulates online is a mix of animal-study doses (reported per kilogram of body weight, not as flat human doses) and dosing ranges used in the small human pilot studies or compounding pharmacy protocols. Treat the table below as a map of what's out there, not a recommendation. | Context | What's reported | Source type |

Can I trust a free online BPC-157 dosage calculator or PDF chart?

Trust it for the arithmetic, not for the target number. A calculator or PDF chart that converts mg to mcg and tells you how many units to draw on a syringe is doing something mechanical and checkable; you can verify the math yourself with the formulas above in under a minute. What you can't verify by checking the tool is whether the dose it defaults to, or the dose you type in, has any basis in controlled human research. A lot of 'BPC-157 dosage calculator pdf' downloads circulating online are really just reformatted vendor dosing charts, sometimes copying numbers from other vendor sites with no traceable source. If a PDF or calculator cites a dose without naming where it came from (a specific study, a specific pharmacy protocol reviewed by a prescriber), that's a red flag, not a convenience. The honest version of this tool tells you plainly: here's the math, here's what's unknown, and here's who should be involved in picking the actual number. A 2026 primer in The American Journal of Sports Medicine on injectable peptide therapy for orthopaedic and sports medicine physicians makes a point relevant here: it frames these peptides as requiring physician-level clinical judgment specifically because standardized dosing evidence is thin ^[16]. That's the same conclusion a 2025 review in Arthroscopy reached when it examined injectable therapeutic peptides as a possible adjunct to regenerative medicine and sports performance, noting the evidence base is still developing relative to how these products are being used in practice ^[17].

What are the safety considerations before using any dosing calculator's output?

Safety data on BPC-157 in humans is limited, and a dosing calculator has no way to flag interactions, contraindications, or injection-site risks specific to you. A 2026 review in Sports Medicine on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is a useful read here, because it draws the line explicitly between peptides with regulatory approval and safety trial data behind them, and unapproved peptides like BPC-157 where that data doesn't yet exist at the same scale ^[18]. Compounded BPC-157 is not sterile-manufactured under the same controls as an approved injectable drug unless it's coming through a licensed compounding pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353a, which sets the conditions under which pharmacy compounding is permitted ^[19]. Sourcing from an unlicensed seller means you have no way to verify sterility, actual peptide content, or contamination, regardless of how precise your dosing math is. Precise math applied to a contaminated or mislabeled vial doesn't protect you. Side effects reported in the small human studies and the broader safety literature include injection site reactions and the general uncertainty that comes with any unapproved compounded product; see our BPC-157 peptide side effects page for the fuller rundown. If you're at the point of actually acquiring and dosing BPC-157, the safer path is working with a provider who reviews your history and orders through a licensed pharmacy, not free-handing a number from a calculator you found through a search.

How does BPC-157 dosing differ for injectable versus other routes?

Injectable dosing (subcutaneous or intra-articular) is what nearly all the calculators and the pilot human studies address; oral and other routes have a much thinner evidence base and different absorption assumptions entirely. The knee pain pilot study used intra-articular injection, meaning directly into the joint space, in a small patient cohort ^[10]. The interstitial cystitis pilot study used its own administration protocol tailored to that condition and patient group ^[11]. Neither generalizes to how you'd dose an oral capsule or a different injection site. A 2014 paper in Current Pharmaceutical Design on BPC-157 and blood vessels reviewed proposed vascular mechanisms, again from animal research, that are sometimes cited to explain why local injection near an injury site is theorized to matter for healing response ^[13]. That's a plausible mechanism from the preclinical literature, not a demonstrated human dosing rule about route selection. If you're comparing routes and frequency, more than calculating volume, our BPC-157 dosage guide covers cycle length and injection timing questions in more depth than a calculator alone can answer. And if you haven't yet nailed down basic pharmacology (half-life, mechanism, what BPC-157 actually is), start with BPC-157 peptide before you start running dosing math.

How does BPC-157 Co fit into using a dosage calculator?

BPC-157 Co doesn't compound or sell BPC-157. What we do is report the study record accurately (the preclinical majority, the small human pilot studies, the regulatory status) so a calculator's output means something in context. If you've done the math and you're ready to move from 'what would this dose look like' to actually obtaining and using BPC-157, the responsible next step is a provider-reviewed process where a prescriber evaluates your situation and the product is dispensed through a licensed compounding pharmacy, not a straight-to-checkout vendor site. That's a meaningfully different path than typing a number into a free calculator and ordering from whoever ranks highest in search results. A calculator can tell you that 250 mcg from a 5 mg vial in 2 mL of water is 0.1 mL. It cannot tell you whether 250 mcg is right for you, whether your kidney or liver function changes anything, or whether the vial you're about to inject was actually made under sterile conditions. Those are the questions a provider and a licensed pharmacy exist to answer. See BPC-157 for sale for more on how sourcing and legal status intersect with the provider-reviewed route.

Frequently asked questions

How do I use a BPC-157 dosage calculator correctly?

Enter the total peptide mass in the vial (mg), the amount of bacteriostatic water you added (mL), and your target dose (mcg). The calculator divides mass by volume for concentration, then divides target dose by concentration for injection volume. It's a math tool for unit conversion, not a source for what your target dose should be; that decision needs a prescriber.

What is a typical BPC-157 reconstitution ratio?

There's no FDA-set standard ratio because BPC-157 isn't an approved drug ^[1]. Compounding pharmacies and prescribers vary in the water volume they specify for a given vial size. Whatever ratio is used, the concentration formula (mass divided by volume) stays the same; only the resulting number changes.

Can a BPC-157 dosage calculator tell me the right dose for my injury?

No. It converts units; it has no clinical judgment. What dose might be appropriate for a specific injury or condition is a prescriber-level decision, and even prescribers are working with limited human evidence, mostly small pilot studies like the 2021 knee pain trial ^[10] and animal research [7, 9], not a validated dose-response standard.

Is there an approved BPC-157 dose in micrograms or milligrams?

No. Check Drugs@FDA yourself: BPC-157 does not appear as an approved drug product ^[1]. Without approval, there's no approved label, no official dosing table, and no agency-reviewed dose range. Any specific number you see quoted online is coming from a study, a pharmacy protocol, or a vendor, not from FDA.

How is a BPC-157/TB-500 blend dosage calculator different from calculating each peptide separately?

A blend calculator has to track two peptide masses in one vial at once. If the vial's BPC-157-to-TB-500 ratio isn't 1:1, you can't independently hit a target dose for each; the ratio in the vial locks the ratio in every draw. Separate single-peptide vials give more independent control over each dose.

Where do BPC-157 dosage calculator PDF charts get their numbers from?

Often from other vendor sites, sometimes ultimately traceable to animal study doses (reported per kg body weight) or small human pilot studies not designed to establish a standard dose. If a PDF doesn't name its source study or protocol, treat its numbers as unverified rather than authoritative.

Is BPC-157 dosing based on human studies or animal studies?

Overwhelmingly animal studies. Reviews on tendon and soft tissue healing ^[7], angiogenic mechanisms ^[8], and tendon cell behavior ^[9] are all rodent or explant research. Human data exists but is limited to small pilot studies on knee pain ^[10] and interstitial cystitis ^[11], not large controlled dosing trials.

Can I convert a rat study dose into a human dose using a calculator?

You shouldn't. Animal doses are typically reported per kilogram of body weight under lab conditions, and species differences in metabolism and absorption make simple weight-based conversion unreliable. No dosing calculator should present a scaled rodent dose as a validated human starting point.

Is BPC-157 legal to buy and use?

BPC-157's status under FDA's compounding bulks lists (21 CFR 216.23 and 216.24) has shifted as the agency reviews nominations ^[2][3], so legality and sourcing depend on current status and how the product is dispensed. Working through a licensed compounding pharmacy under section 503A ^[19] is the compliant route; see our BPC-157 for sale page for current detail.

What are the risks of miscalculating a BPC-157 dose?

Under-dosing wastes product and likely delivers no meaningful effect; over-dosing increases exposure beyond anything studied in humans, since no human maximum tolerated dose has been formally established. Beyond the math, product quality (sterility, actual peptide content) matters just as much as getting the volume right; see our BPC-157 peptide side effects page.

Does a dosage calculator account for injection route (subcutaneous vs intra-articular)?

A basic calculator only handles volume math; it doesn't adjust for route. Route matters clinically. The 2021 knee pain pilot study used intra-articular injection into the joint space ^[10], while other protocols use subcutaneous injection; these aren't interchangeable and route selection should be a prescriber decision, not a calculator setting.

How many human clinical trials exist for BPC-157 dosing?

Very few, and small. The main examples in the current literature are a 2021 pilot study on intra-articular BPC-157 for knee pain ^[10] and a 2024 pilot study on interstitial cystitis symptoms ^[11]. Neither is a large randomized dose-ranging trial, so no formal human dose-response curve has been established.

Sources

1. Drugs@FDA, FDA-approved drug products database: BPC-157 does not appear as an FDA-approved drug product, meaning there is no FDA-approved human dose.
2. 21 CFR 216.23, the final 503A Bulks List: Defines which bulk drug substances licensed compounding pharmacies may use for individual patient compounding under section 503A.
3. 21 CFR 216.24, the 503B Bulks List: Defines which bulk drug substances outsourcing facilities compounding under section 503B may use.
4. FDA, bulk drug substances used in compounding under section 503A: Explains FDA's standard for evaluating bulk drug substances nominated for use in 503A compounding.
5. FDA, bulk drug substances nominated for use in compounding (current list): Lists substances, including BPC-157, currently under FDA review status for compounding use, which can change over time.
6. Pharmaceuticals (Basel), 2025 (PMID 40005999): Literature and patent review cataloguing proposed BPC-157 mechanisms and applications, based predominantly on preclinical research.
7. Cell and Tissue Research, 2019 (PMID 30915550): Reviews BPC-157's role in accelerating musculoskeletal soft tissue healing in animal models of tendon, ligament, and muscle.
8. Current Pharmaceutical Design, 2018 (PMID 29998800): Reviews BPC-157 and angiogenic growth factors in gastrointestinal, tendon, ligament, muscle, and bone healing in animal studies.
9. Journal of Applied Physiology, 2011 (PMID 21030672): Found BPC-157 promoted tendon outgrowth, cell survival, and cell migration in an explant/rat model of tendon healing.
10. Alternative Therapies in Health and Medicine, 2021 (PMID 34324435): Small human pilot study on intra-articular BPC-157 injection for multiple types of knee pain.
11. Alternative Therapies in Health and Medicine, 2024 (PMID 39325560): Small human pilot study examining BPC-157's effect on symptoms in patients with interstitial cystitis.
12. HSS Journal, 2025 (PMID 40756949): Systematic review of BPC-157's emerging use in orthopaedic sports medicine, summarizing the current clinical evidence base.
13. Current Pharmaceutical Design, 2014 (PMID 23782145): Reviews proposed BPC-157 vascular mechanisms from animal research, relevant to theories about local injection and healing.
14. Current Reviews in Musculoskeletal Medicine, 2025 (PMID 40789979): Narrative review weighing preclinical mechanistic promise of BPC-157 against gaps in human safety and efficacy evidence.
15. JAAOS Global Research & Reviews, 2026 (PMID 41490200): Reviews therapeutic peptides in orthopaedics broadly, noting gaps between mechanistic interest and clinical validation.
16. American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for physicians framing injectable peptide therapy as requiring clinical judgment given thin standardized dosing evidence.
17. Arthroscopy, 2025 (PMID 39265666): Reviews injectable therapeutic peptides as a possible adjunct to regenerative medicine and sports performance, noting an evidence base still developing relative to use in practice.
18. Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy differences between approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance.
19. 21 U.S.C. 353a, pharmacy compounding: Sets the statutory conditions under which licensed pharmacy compounding of drug products, including under section 503A, is permitted.